Drug intelligence / Profile preview

UPV-103

Development stage: Preclinical
Lead developer: UbiVac
Modality: Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics

Overview

UPV-103 is a therapeutic vaccine developed by UbiVac. It is designed as a ubiquitinylated protein vaccine, which suggests it leverages the process of ubiquitination to enhance immune recognition of target antigens. The primary therapeutic areas under investigation are neoplasms (cancers) and dysplasia, with preclinical development status as of early 2025. The specific mechanism of action and molecular targets have not been disclosed in public sources, but as a therapeutic cancer vaccine, it likely aims to stimulate an anti-tumor immune response by presenting tumor-associated antigens in a way that enhances immunogenicity[1][2][3].

Other names: Ubiquitinylated Protein Vaccine UPV-103

Targets

TAA/DGA (Tumor-associated and dark genome cancer antigens)

Beyond the preview

Go deeper on UPV-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UPV-103.

Explore the full profile